



© Copyright 2012 Oregon State University. All Rights Reserved

Drug Use Research & Management Program
OHA Division of Medical Assistance Programs
500 Summer Street NE, E35; Salem, OR 97301-1079
Phone 503-947-5220 | Fax 503-947-1119



Oregon Drug Use Review / Pharmacy & Therapeutics Committee

Thursday, February 5th, 2026 1:00 - 5:00 PM

Remote Meeting via Zoom Platform

MEETING AGENDA

NOTE: Any agenda items discussed by the DUR/P&T Committee may result in changes to utilization control recommendations to the OHA. Timing, sequence and inclusion of agenda items presented to the Committee may change at the discretion of the OHA, P&T Committee and staff. The DUR/P&T Committee functions as the Rules Advisory Committee to the Oregon Health Plan for adoption into Oregon Administrative Rules 410-121-0030 & 410-121-0040 in accordance with Oregon Revised Statute 183.333.

I. CALL TO ORDER

- | | | |
|---------|---|---|
| 1:00 PM | <ul style="list-style-type: none"> A. Roll Call & Introductions B. Conflict of Interest Declaration C. Election of Chair and Vice-chair D. Approval of Agenda and Minutes E. Department Update F. Legislative Update G. Mental Health Clinical Advisory Group Update | <ul style="list-style-type: none"> R. Citron (OSU) R. Citron (OSU) R. Citron (OSU) R. Citron (OSU) A. Gibler (OHA) D. Weston (OHA) A. Gibler (OHA) |
|---------|---|---|

- | | | |
|---------|--|---------|
| 1:20 PM | <h4>II. CONSENT AGENDA TOPICS</h4> <ul style="list-style-type: none"> A. Oncology Prior Authorization Updates B. Orphan Drug Policy Updates <ul style="list-style-type: none"> 1. Public Comment | (Chair) |
|---------|--|---------|

- | | | |
|---------|---|---|
| 1:25 PM | <h4>III. DUR ACTIVITIES</h4> <ul style="list-style-type: none"> A. Quarterly Utilization Report B. ProDUR Report C. RetroDUR Report D. Oregon State Drug Review | <ul style="list-style-type: none"> R. Citron (OSU) L. Starkweather (Gainwell) D. Engen (OSU) K. Sentena (OSU) |
|---------|---|---|

IV. NEW BUSINESS

- | | | |
|---------|---|------------------|
| 1:45 PM | <ul style="list-style-type: none"> A. Antidepressant Class Update <ul style="list-style-type: none"> 1. Class Update/Prior Authorization Criteria 2. Public Comment 3. Discussion and Clinical Recommendations to OHA | K. Sentena (OSU) |
| 2:00 PM | <ul style="list-style-type: none"> B. Tryngolza® (Olezarsen) New Drug Evaluation <ul style="list-style-type: none"> 1. New Drug Evaluation/Prior Authorization Criteria 2. Public Comment 3. Discussion and Clinical Recommendations | M. Herink (OSU) |

- 2:15 PM C. Wegovy® (semaglutide) Prior Authorization for MASH S. Fletcher (OSU)
1. Prior Authorization Criteria
 2. Public Comment
 3. Discussion and Clinical Recommendations to OHA
- 2:30 PM BREAK
- 2:45 PM D. Sedatives for Insomnia Class Update D. Engen (OSU)
1. Class Update/Prior Authorization Criteria
 2. Public Comment
 3. Discussion and Clinical Recommendations to OHA
- 3:00 PM E. Medications for Allergies D. Moretz (OSU)
1. Nasal Inhalers, Oral 1st and 2nd Generation antihistamines Class Update
 2. Eye Drops for Allergies Class Review
 3. Prior Authorization Criteria
 4. Public Comment
 5. Discussion and Clinical Recommendations to OHA
- 3:30 PM F. Forzinity™ (elamipretide) Abbreviated New Drug Evaluation S. Servid (OSU)
1. Class Update/Prior Authorization Criteria
 2. Public Comment
 3. Discussion and Clinical Recommendations to OHA
- 3:50 PM VI. EXECUTIVE SESSION
- 4:50 PM VII. RECONVENE for PUBLIC RECOMMENDATIONS
- VIII. ADJOURN